Cipla reported INR131.3M in Interest Expense on Debt for its fiscal quarter ending in March of 2026.





Interest Expense On Debt Change Date
Arca Biopharma USD 504K 246K Sep/2024
aTyr Pharma 79.65M 78.89M Mar/2026
Bio Path 677K 547K Mar/2026
Capricor Therapeutics 3.05M 2.46M Dec/2025
Cara Therapeutics -89.64M 128.67M Dec/2025
Cipla INR 131.3M 9M Mar/2026
Dr.Reddys Laboratories INR 1.06B 113M Mar/2026
Esperion Therapeutics USD 22.64M 585K Dec/2025
Immunic 197K 222K Dec/2025
Infinity Pharmaceuticals USD 45K 0 Jun/2023
Minerva Neurosciences USD 2.31M 60K Jun/2024
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sun Pharmaceuticals INR 998.6M 250.6M Sep/2025
TherapeuticsMD USD 20K 25K Sep/2023
UPL INR 7.74B 210M Dec/2025